Texas-based plasmid DNA manufacturer VGXI, Inc. recognized as a finalist for Best CMO for the ViE Awards of the World Vaccine Congress
THE WOODLANDS, TEXAS (PRWEB) MARCH 04, 2020
VGXI, Inc., a uniquely specialized CDMO providing high quality plasmid DNA-based products and services, announced it has been nominated as a finalist in the category of Best Contract Manufacturing Organization for the annual Vaccine Industry Excellence (ViE) Awards. This nomination comes as VGXI expedites manufacturing of a DNA vaccine against the novel coronavirus, COVID-19, under a CEPI funded collaboration.
The ViE Awards highlight the accomplishments and positive contributions of companies and individuals across the vaccine industry. Shortlisted finalists for each of the 12 award categories are determined by industry nominations and voting over a 3 month period. The ViE Scientific Advisory Board oversees the final judging round.
“VGXI’s nomination for Best CMO is a testament to our company’s reputation among industry leaders, our clients, and our partners,” stated VGXI COO Dorothy Peterson. “With nearly 20 years of experience, we have established a track record of success in delivering exceptional results for our client’s challenging projects.”
As part of the annual World Vaccine Congress in Washington DC, winners in each category will be announced at the ViE Awards Ceremony & Gala Dinner on April 7th, 2020.
VGXI will also be exhibiting at Booth #310 during the WVC conference. Requests for partnering meetings during the event are welcome and can be submitted at the VGXI website: http://vgxii.com/contact-us/
ABOUT VGXI, INC.
VGXI, Inc. is a leading provider of manufacturing and development services for DNA vaccines and gene therapies. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CDMO of GeneOne Life Science, Inc. To learn more, visit http://www.vgxii.com.
ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) is an international DNA vaccine and product developer, and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines and products to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne’s wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. For more information, visit http://www.genels.com/en.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.
VGXI’s nomination for Best CMO is a testament to our company’s reputation among industry leaders, our clients, and our partners.
